How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/exercise-induced-bronchospasm-prevention.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Exercise-Induced Bronchospasm Prevention — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Exercise-Induced Bronchospasm Prevention (disease) competitive landscape: 6 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

6 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Exercise-Induced Bronchospasm Prevention, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Foradil	FORMOTEROL	Novartis	beta2-Adrenergic Agonist	Beta-2 adrenergic receptor	2001-01-01
Singulair	montelukast	Merck & Co.	Leukotriene receptor antagonist (LTRA)	Cytochrome P450 2C8, Adenosine receptor A3, Cysteinyl leukotriene receptor 2	1998-02-20
ProAir	albuterol	Generic (originally Allen & Hanburys/GSK)	SABA (Short-acting beta-2 agonist)	Beta-1 adrenergic receptor, Beta-2 adrenergic receptor, Beta-2 adrenergic receptor	1982-05-05
Proventil	salbutamol	Merck & Co.	beta2-Adrenergic Agonist	Beta-2 adrenergic receptor	1981-01-01
Singulair	Singulair	Genuine Research Center, Egypt		Cytochrome P450 2C8, Adenosine receptor A3, Cysteinyl leukotriene receptor 2
Serevent	Serevent	Fundacio Privada Mon Clinic Barcelona		Aldehyde oxidase, Beta-1 adrenergic receptor, Beta-2 adrenergic receptor

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Merck & Co. · 2 drugs in Exercise-Induced Bronchospasm Prevention
Fundacio Privada Mon Clinic Barcelona · 1 drug in Exercise-Induced Bronchospasm Prevention
Generic (originally Allen & Hanburys/GSK) · 1 drug in Exercise-Induced Bronchospasm Prevention
Genuine Research Center, Egypt · 1 drug in Exercise-Induced Bronchospasm Prevention
Novartis · 1 drug in Exercise-Induced Bronchospasm Prevention

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Exercise-Induced Bronchospasm Prevention:

Cite this brief

Drug Landscape (2026). Exercise-Induced Bronchospasm Prevention — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/exercise-induced-bronchospasm-prevention. Accessed 2026-06-10.

Exercise-Induced Bronchospasm Prevention full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing